Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters

Rhea-AI Summary

Terumo Neuro (OTC:TRUMY) has revealed new real-world physician preference data for its SOFIA™ 88 Neurovascular Support Catheter at the 2025 SNIS Annual Meeting. The data, collected from 105 procedures across 37 U.S. centers and 41 physicians, demonstrates strong performance compared to other super-bore catheters.

Key findings show that 95% of physicians reported reliable target location reach, and 86% rated SOFIA™ 88 as "Better" or "Much Better" than alternatives. The catheter outperformed competitors significantly, beating ZOOM 88 in 94% of cases and HiPoint 88 in 79% of cases.

The SOFIA™ 88 catheter, launched in the U.S. on May 13, 2025, is part of Terumo Neuro's integrated stroke solution portfolio, which includes the ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, and other specialized medical devices.

Positive

• 95% physician success rate in reaching target locations, even in challenging anatomies
• 86% of physicians rated SOFIA™ 88 as Better or Much Better than alternatives
• Outperformed competitors with 94% success vs ZOOM 88 and 79% vs HiPoint 88
• Successfully launched and integrated into comprehensive stroke solution portfolio

Negative

• None.

Real-World U.S. Physician Preference Data¹ Demonstrates the SOFIA™ 88 Catheter's Trackability, Atraumatic Design, and Overall Performance in Stroke Procedures

NASHVILLE, Tenn., July 14, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. The data—presented publicly for the first time —demonstrates strong performance compared to other super-bore catheters in key performance metrics such as trackability, atraumatic design and overall physician-rated experience.

Collected from 105 procedures across 37 U.S. centers and 41 physicians, the preference test revealed:

• 95% of physicians reported that SOFIA™ 88 catheter reliably reached the target location—even in anatomically challenging cases, with 59% of procedures in ICA-T or beyond
• 86% of physicians rated the SOFIA™ 88 catheter as "Better" or "Much Better" than alternatives overall
• Physician data included: SOFIA™ 88 catheter outperformed the ZOOM 88 catheter in 94% of cases and the HiPoint 88 catheter in 79%

"These real-world results further validate SOFIA™ 88 catheter's position as a leading super-bore support catheter," said Carsten Schroeder, President and CEO of Terumo Neuro. "This new dataset reinforces what we've heard consistently from physicians: the SOFIA™ 88 catheter delivers reliable performance where it matters most. We are proud to see the catheter outperform other large-bore devices in real-world settings—and even more proud that this innovation was shaped through close physician partnership. It reflects our long-standing commitment to delivering meaningful neurovascular advancements rooted in evidence, experience, and collaboration."

The SOFIA™ 88 Neurovascular Support Catheter was commercially launched in the U.S. on May 13, 2025, as the latest addition to Terumo Neuro's global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA™ 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies.

The physician preference data unveiled at SNIS builds on results from the SOFAST registry, which demonstrated the safety and efficacy of the SOFIA™ Flow Plus 6F catheter as a frontline aspiration device.

The SOFIA™ 88 catheter is compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter and is part of Terumo Neuro's fully integrated stroke solution, including:

• ERIC™ Retrieval Device – For thrombus control and procedural versatility
• BOBBY™ Balloon Guide Catheter – Offering reliable flow arrest with next-gen balloon technology
• WEDGE™ and HEADWAY™ Microcatheters – Designed for navigation support and access efficiency
• TRAXCESS™ Guidewires – Soft-tip wires built for challenging anatomies

About Terumo Neuro

We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neurovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Reference

1. Data on file

Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
christine.mccullough@terumoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-neuro-unveils-new-sofia-88-catheter-data-demonstrating-strong-performance-compared-to-other-super-bore-catheters-302503950.html

SOURCE Terumo Neuro

FAQ

What are the key performance metrics of Terumo's SOFIA™ 88 catheter according to the 2025 physician preference data?

According to the data, 95% of physicians reported reliable target location reach, and 86% rated it Better or Much Better than alternatives. The catheter outperformed ZOOM 88 in 94% of cases and HiPoint 88 in 79% of cases.

When was the SOFIA™ 88 Neurovascular Support Catheter launched in the US market?

The SOFIA™ 88 catheter was commercially launched in the United States on May 13, 2025.

How many procedures and physicians were involved in Terumo's SOFIA™ 88 catheter study?

The study included 105 procedures across 37 U.S. centers, involving 41 physicians.

What other products are included in Terumo Neuro's stroke solution portfolio?

Terumo's integrated stroke solution includes the ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, WEDGE™ and HEADWAY™ Microcatheters, and TRAXCESS™ Guidewires.

How did SOFIA™ 88 perform in anatomically challenging cases?

The data showed that 95% of physicians reported reliable target location reach, with 59% of procedures successfully performed in ICA-T or beyond, demonstrating strong performance in anatomically challenging cases.